Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Colorcon
Merck
AstraZeneca
Moodys

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for AV-101


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug AV-101?

AV-101 is an investigational drug.

There have been 5 clinical trials for AV-101. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2021.

The most common disease conditions in clinical trials are Dyskinesia, Drug-Induced, Depressive Disorder, Major, and Pulmonary Arterial Hypertension. The leading clinical trial sponsors are VistaGen Therapeutics, Inc., Michael Debakey Veterans Affairs Medical Center, and Michael E. DeBakey VA Medical Center.

There are twenty-six US patents protecting this investigational drug and two hundred and sixty-five international patents.

Recent Clinical Trials for AV-101
TitleSponsorPhase
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiaVistaGen Therapeutics, Inc.Phase 2
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)Aerovate TherapeuticsPhase 2/Phase 3
Electrophysiological Biomarkers of AV-101Michael Debakey Veterans Affairs Medical CenterPhase 1/Phase 2

See all AV-101 clinical trials

Clinical Trial Summary for AV-101

Top disease conditions for AV-101
Top clinical trial sponsors for AV-101

See all AV-101 clinical trials

US Patents for AV-101

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AV-101 ⤷  Try it Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try it Free
AV-101 ⤷  Try it Free Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) ⤷  Try it Free
AV-101 ⤷  Try it Free Methods for the synthesis of chiral kynurenine compounds VISTAGEN THERAPEUTICS, INC. (South San Francisco, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Colorcon
Merck
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.